Nanotechnology and curcumin: a novel and promising approach in digestive cancer therapy

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. Arnold M, Abnet CC, Neale RE et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1), 335–349.e15 (2020).
  MedlineGoogle Scholar
• 2. Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019. J. Hematol. Oncol. 14(1), 197 (2021).
  MedlineGoogle Scholar
• 3. Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr. Opin. Oncol. 32(4), 356–363 (2020).
  MedlineGoogle Scholar
• 4. Li C, Wang J, Wang Y et al. Recent progress in drug delivery. Acta Pharm. Sin. B 9(6), 1145–1162 (2019).
  MedlineGoogle Scholar
• 5. Seelinger M, Popescu R, Giessrigl B et al. Methanol extract of the ethnopharmaceutical remedy Smilax spinosa exhibits anti-neoplastic activity. Int. J. Oncol. 41(3), 1164–1172 (2012).
  MedlineGoogle Scholar
• 6. Kim D-W, Choi C-H, Park JP, Lee S-J. Nanospheres loaded with curcumin improve the bioactivity of umbilical cord blood-mesenchymal stem cells via c-Src activation during the skin wound healing process. Cells 9(6), 1467 (2020).
  Medline CASGoogle Scholar
• 7. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol. Nutr. Food Res. 57(9), 1510–1528 (2013).
  Medline CASGoogle Scholar
• 8. Sinha D, Biswas J, Sung B, Aggarwal B, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr. Drug Targets 13(14), 1799–1819 (2012).
  Medline CASGoogle Scholar
• 9. Song X, Zhang M, Dai E, Luo Y. Molecular targets of curcumin in breast cancer. Mol. Med. Rep. 19(1), 23–29 (2019). •• Reviews the chemistry and bioavailability of curcumin and its molecular targets in breast cancer.
  Medline CASGoogle Scholar
• 10. Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol. 28(8), 393–399 (2016).
  Medline CASGoogle Scholar
• 11. Singh A, Kim W, Kim Y et al. Multifunctional photonics nanoparticles for crossing the blood–brain barrier and effecting optically trackable brain theranostics. Adv. Funct. Mater. 26(39), 7057–7066 (2016).
  Medline CASGoogle Scholar
• 12. Klippstein R, Wang JTW, El-Gogary RI et al. Passively targeted curcumin-loaded pegylated PLGA nanocapsules for colon cancer therapy in vivo. Small 11(36), 4704–4722 (2015).
  Medline CASGoogle Scholar
• 13. Bhatia SN, Chen X, Dobrovolskaia MA, Lammers T. Cancer nanomedicine. Nat. Rev. Cancer 22(10), 550–556 (2022).
  Medline CASGoogle Scholar
• 14. Zhang C, Yan L, Wang X et al. Progress, challenges, and future of nanomedicine. Nano. Today 35, 101008 (2020).
  CASGoogle Scholar
• 15. Xiang J, Zhao R, Wang B et al. Advanced nano-carriers for anti-tumor drug loading. Front. Oncol. 11, 758143 (2021).
  Medline CASGoogle Scholar
• 16. Reshmitha T, Shini V, Nisha P. Nanotechnology approaches for colorectal cancer diagnosis and therapy. In: Colon Cancer Diagnosis and Therapy: Volume 2. Springer, Cham, Switzerland, 171–186 (2021).
  Google Scholar
• 17. Sardou HS, Nazari SE, Abbaspour M et al. Nano-curcumin formulations for targeted therapy of colorectal cancer. J. Drug. Deliv. Sci. Technol. 88, 104943 (2023).
  CASGoogle Scholar
• 18. Meybodi SM, Rezaei P, Faraji N et al. Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: new trends and future perspectives in cancer therapy. J. Funct. Foods 108, 105705 (2023).
  CASGoogle Scholar
• 19. Kang Y, Hu W, Bai E et al. Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NF-κB survival-signaling pathway. Onco. Targets Ther. 9, 7373–7384 (2016).
  Medline CASGoogle Scholar
• 20. Rezaei-Tazangi F, Roghani-Shahraki H, Khorsand Ghaffari M et al. The therapeutic potential of common herbal and nano-based herbal formulations against ovarian cancer: new insight into the current evidence. Pharmaceuticals 14(12), 1315 (2021).
  Medline CASGoogle Scholar
• 21. He G, Mu T, Yuan Y et al. Effects of notch signaling pathway in cervical cancer by curcumin mediated photodynamic therapy and its possible mechanisms in vitro and in vivo. J. Cancer 10(17), 4114 (2019).
  Medline CASGoogle Scholar
• 22. Li B, Shi C, Li B, Zhao JM, Wang L. The effects of curcumin on HCT-116 cells proliferation and apoptosis via the miR-491/PEG10 pathway. J. Cell. Biochem. 119(4), 3091–3098 (2018).
  Medline CASGoogle Scholar
• 23. Banerjee S, Ji C, Mayfield JE et al. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proc. Natl Acad. Sci. USA 115(32), 8155–8160 (2018).
  Medline CASGoogle Scholar
• 24. Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl. Oncol. 13(6), 100773 (2020).
  MedlineGoogle Scholar
• 25. Li W, Jiang Z, Xiao X et al. Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Int. J. Oncol. 52(5), 1593–1602 (2018).
  Medline CASGoogle Scholar
• 26. Namkaew J, Jaroonwitchawan T, Rujanapun N, Saelee J, Noisa P. Combined effects of curcumin and doxorubicin on cell death and cell migration of SH-SY5Y human neuroblastoma cells. In Vitro Cell. Dev. Biol. Anim. 54, 629–639 (2018).
  Medline CASGoogle Scholar
• 27. Choe SR, Kim YN, Park CG, Cho KH, Cho DY, Lee HY. RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. Exp. Mol. Med. 50(4), 1–10 (2018).
  CASGoogle Scholar
• 28. Chimento A, D’Amico M, De Luca A, Conforti FL, Pezzi V, De Amicis F. Resveratrol, epigallocatechin gallate and curcumin for cancer therapy: challenges from their pro-apoptotic properties. Life 13(2), 261 (2023).
  Medline CASGoogle Scholar
• 29. Wang C, Yu F, Liu X et al. Cancer-specific therapy by artificial modulation of intracellular calcium concentration. Adv. Healthc. Mater. 8(18), 1900501 (2019).
  Google Scholar
• 30. Méndez-García L, Martinez-Castillo M, Villegas-Sepulveda N, Orozco L, Córdova E. Curcumin induces p53-independent inactivation of Nrf2 during oxidative stress-induced apoptosis. Hum. Exp. Toxicol. 38(8), 951–961 (2019).
  Medline CASGoogle Scholar
• 31. Liu L-D, Pang Y-X, Zhao X-R et al. Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells. Arch. Gynecol. Obstet. 299, 1627–1639 (2019).
  Medline CASGoogle Scholar
• 32. Chen P, Huang H-P, Wang Y et al. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J. Exp. Clin. Cancer Res. 38(1), 1–17 (2019).
  MedlineGoogle Scholar
• 33. Yoysungnoen-Chintana P, Bhattarakosol P, Patumraj S. Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice. Biomed. Res. Int. 2014, 817972 (2014).
  MedlineGoogle Scholar
• 34. Da W, Zhang J, Zhang R, Zhu J. Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling. Int. J. Immunopathol. Pharmacol. 33, 2058738419861600 (2019).
  Google Scholar
• 35. Najafi M, Farhood B, Mortezaee K et al. Contribution of regulatory T cells to cancer: A review. J. Cell. Physiol. 234(6), 7983–7993 (2019).
  Medline CASGoogle Scholar
• 36. Xu B, Yu L, Zhao L-Z. Curcumin up regulates T helper 1 cells in patients with colon cancer. Am. J. Transl. Res. 9(4), 1866 (2017).
  Medline CASGoogle Scholar
• 37. Zhao H-M, Xu R, Huang X-Y et al. Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice. World J. Gastroenterol. 22(23), 5374 (2016).
  Medline CASGoogle Scholar
• 38. Mukherjee S, Baidoo JN, Fried A, Banerjee P. Using curcumin to turn the innate immune system against cancer. Biochem. Pharmacol. 176, 113824 (2020).
  Medline CASGoogle Scholar
• 39. Mukherjee S, Fried A, Hussaini R et al. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. J. Exp. Clin. Cancer Res. 37(1), 1–18 (2018).
  MedlineGoogle Scholar
• 40. Zhang Y, Li Q, Huang Z et al. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers 14(19), 4568 (2022).
  Medline CASGoogle Scholar
• 41. Monteleone F, Taverna S, Alessandro R, Fontana S. SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1κ axis. J. Exp. Clin. Cancer Res. 37(1), 1–18 (2018).
  MedlineGoogle Scholar
• 42. Siddiqui FA, Prakasam G, Chattopadhyay S et al. Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition. Sci. Rep. 8(1), 8323 (2018).
  MedlineGoogle Scholar
• 43. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer. 18(7), 452–464 (2018).
  Medline CASGoogle Scholar
• 44. He W-T, Zhu Y-H, Zhang T et al. Curcumin reverses 5-fluorouracil resistance by promoting human colon cancer HCT-8/5-FU cell apoptosis and down-regulating heat shock protein 27 and P-glycoprotein. Chin. J. Integr. Med. 25, 416–424 (2019).
  Medline CASGoogle Scholar
• 45. Yoshida K, Toden S, Ravindranathan P, Han H, Goel A. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis 38(10), 1036–1046 (2017).
  Medline CASGoogle Scholar
• 46. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 20(2–3), 251–257 (1981).
  Medline CASGoogle Scholar
• 47. Wang Y-J, Pan M-H, Cheng A-L et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 15(12), 1867–1876 (1997).
  Medline CASGoogle Scholar
• 48. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. 43(2), 86–92 (1978).
  Medline CASGoogle Scholar
• 49. Ireson C, Orr S, Jones DJ et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61(3), 1058–1064 (2001).
  Medline CASGoogle Scholar
• 50. Ireson CR, Jones DJ, Orr S et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 11(1), 105–111 (2002).
  Medline CASGoogle Scholar
• 51. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin: miniperspective. J. Med. Chem. 60(5), 1620–1637 (2017).
  Medline CASGoogle Scholar
• 52. Mahal A, Wu P, Jiang ZH, Wei X. Synthesis and cytotoxic activity of novel tetrahydrocurcumin derivatives bearing pyrazole moiety. Nat. Prod. Bioprospect. 7(6), 461–469 (2017).
  Medline CASGoogle Scholar
• 53. Nardo L, Andreoni A, Masson M, Haukvik T, Tonnesen HH. Studies on curcumin and curcuminoids. XXXIX. Photophysical properties of bisdemethoxycurcumin. J. Fluoresc. 21(2), 627–635 (2011).
  Medline CASGoogle Scholar
• 54. Adeluola A, Zulfiker AHM, Brazeau D, Amin A. Perspectives for synthetic curcumins in chemoprevention and treatment of cancer: an update with promising analogues. Eur. J. Pharmacol. 906, 174266 (2021).
  Medline CASGoogle Scholar
• 55. Luo SM, Wu YP, Huang LC, Huang SM, Hueng DY. The anti-cancer effect of four curcumin analogues on human glioma cells. Onco. Targets Ther. 14, 4345–4359 (2021).
  MedlineGoogle Scholar
• 56. Momtazi AA, Sahebkar A. Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr. Pharm. Des. 22(28), 4386–4397 (2016).
  Medline CASGoogle Scholar
• 57. Shen H, Shen J, Pan H et al. Curcumin analog B14 has high bioavailability and enhances the effect of anti-breast cancer cells in vitro and in vivo. Cancer Sci. 112(2), 815–827 (2021).
  Medline CASGoogle Scholar
• 58. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. 30(1), 74–78 (2007).
  Medline CASGoogle Scholar
• 59. Padhye S, Banerjee S, Chavan D et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 26(11), 2438–2445 (2009).
  Medline CASGoogle Scholar
• 60. Reid JM, Buhrow SA, Gilbert JA et al. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993). Cancer Chemother. Pharmacol. 73(6), 1137–1146 (2014).
  Medline CASGoogle Scholar
• 61. Bertazza L, Sensi F, Cavedon E et al. EF24 (a curcumin analog) and ZSTK474 emphasize the effect of cabozantinib in medullary thyroid cancer. Endocrinology 159(6), 2348–2360 (2018).
  Medline CASGoogle Scholar
• 62. Wu X, Tang W, Marquez RT et al. Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget 7(10), 11708–11723 (2016).
  MedlineGoogle Scholar
• 63. Anisuzzaman AS, Haque A, Rahman MA et al. Preclinical in vitro, in vivo, and pharmacokinetic evaluations of FLLL12 for the prevention and treatment of head and neck cancers. Cancer Prev. Res. 9(1), 63–73 (2016).
  Medline CASGoogle Scholar
• 64. Basak SK, Zinabadi A, Wu AW et al. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells. Oncotarget 6(21), 18504–18517 (2015).
  MedlineGoogle Scholar
• 65. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ. Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest. New Drugs 29(1), 87–97 (2011).
  Medline CASGoogle Scholar
• 66. Zhang J, Feng Z, Wang C et al. Curcumin derivative WZ35 efficiently suppresses colon cancer progression through inducing ROS production and ER stress-dependent apoptosis. Am. J. Cancer Res. 7(2), 275–288 (2017).
  Medline CASGoogle Scholar
• 67. Chuprajob T, Changtam C, Chokchaisiri R, Chunglok W, Sornkaew N, Suksamrarn A. Synthesis, cytotoxicity against human oral cancer KB cells and structure–activity relationship studies of trienone analogues of curcuminoids. Bioorg. Med. Chem. Lett. 24(13), 2839–2844 (2014).
  Medline CASGoogle Scholar
• 68. Lin C, Tu C, Ma Y et al. Curcumin analog EF24 induces apoptosis and downregulates the mitogen activated protein kinase/extracellular signal-regulated signaling pathway in oral squamous cell carcinoma. Mol. Med. Rep. 16(4), 4927–4933 (2017).
  Medline CASGoogle Scholar
• 69. Murakami M, Ohnuma S, Fukuda M et al. Synthetic analogs of curcumin modulate the function of multidrug resistance-linked ATP-binding cassette transporter ABCG2. Drug Metab. Dispos. 45(11), 1166–1177 (2017).
  Medline CASGoogle Scholar
• 70. Chen W, Zou P, Zhao Z et al. Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation. Oncotarget 7(13), 16593–16609 (2016).
  MedlineGoogle Scholar
• 71. Zhou B, Zuo Y, Li B et al. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells. Mol. Cancer Ther. 12(8), 1381–1392 (2013).
  Medline CASGoogle Scholar
• 72. Xiong Y, Guo D, Wang L, Zheng X, Zhang Y, Chen J. Development of nobiliside A loaded liposomal formulation using response surface methodology. Int. J. Pharm. 371(1–2), 197–203 (2009).
  Medline CASGoogle Scholar
• 73. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125(1), 1–8 (2009).
  Medline CASGoogle Scholar
• 74. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 32(5), 1119–1123 (2008).
  Medline CASGoogle Scholar
• 75. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly (butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm. 7(3), 815–825 (2010).
  Medline CASGoogle Scholar
• 76. Rejinold NS, Muthunarayanan M, Divyarani V et al. Curcumin-loaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery. J. Colloid Interface Sci. 360(1), 39–51 (2011).
  MedlineGoogle Scholar
• 77. Kim TH, Jiang HH, Youn YS et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int. J. Pharm. 403(1–2), 285–291 (2011).
  Medline CASGoogle Scholar
• 78. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm. 398(1–2), 190–203 (2010).
  Medline CASGoogle Scholar
• 79. Hudson EA, De Paula HMC, Da Silva RM, Dos Santos Pires AC, Da Silva LHM. Curcumin-micellar casein multisite interactions elucidated by surface plasmon resonance. Int. J. Biol. Macromol. 133, 860–866 (2019).
  Medline CASGoogle Scholar
• 80. Raemdonck K, Demeester J, De Smedt S. Advanced nanogel engineering for drug delivery. Soft Matter 5(4), 707–715 (2009).
  CASGoogle Scholar
• 81. Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials 32(2), 598–609 (2011).
  Medline CASGoogle Scholar
• 82. Mangalathillam S, Rejinold NS, Nair A, Lakshmanan V-K, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale 4(1), 239–250 (2012).
  Medline CASGoogle Scholar
• 83. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J. Pharm. Sci. 100(5), 1987–1995 (2011).
  Medline CASGoogle Scholar
• 84. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 60, 171–177 (2007).
  Medline CASGoogle Scholar
• 85. Podlogar F, Gašperlin M, Tomšič M, Jamnik A, Rogač MB. Structural characterisation of water–Tween 40^®/Imwitor 308^®–isopropyl myristate microemulsions using different experimental methods. Int. J. Pharm. 276(1–2), 115–128 (2004).
  Medline CASGoogle Scholar
• 86. Zhang W, Ma W, Zhang J, Song X, Sun W, Fan Y. The immunoregulatory activities of astragalus polysaccharide liposome on macrophages and dendritic cells. Int. J. Biol. Macromol. 105, 852–861 (2017).
  Medline CASGoogle Scholar
• 87. Akhavan S, Assadpour E, Katouzian I, Jafari SM. Lipid nano scale cargos for the protection and delivery of food bioactive ingredients and nutraceuticals. Trends Food Sci. Tech. 74, 132–146 (2018).
  CASGoogle Scholar
• 88. Ghorbanzade T, Jafari SM, Akhavan S, Hadavi R. Nano-encapsulation of fish oil in nano-liposomes and its application in fortification of yogurt. Food Chem. 216, 146–152 (2017).
  Medline CASGoogle Scholar
• 89. Shityakov S, Salmas RE, Durdagi S, Roewer N, Förster C, Broscheit J. Solubility profiles, hydration and desolvation of curcumin complexed with γ-cyclodextrin and hydroxypropyl-γ-cyclodextrin. J. Mol. Struct. 1134, 91–98 (2017).
  CASGoogle Scholar
• 90. He C, Zhang X, Yan R et al. Enhancement of cisplatin efficacy by lipid–CaO₂ nanocarrier-mediated comprehensive modulation of the tumor microenvironment. Biomater. Sci. 7(10), 4260–4272 (2019).
  Medline CASGoogle Scholar
• 91. Chen X, Zou L-Q, Niu J, Liu W, Peng S-F, Liu C-M. The stability, sustained release and cellular antioxidant activity of curcumin nanoliposomes. Molecules 20(8), 14293–14311 (2015).
  Medline CASGoogle Scholar
• 92. Jiang H, Geng D, Liu H, Li Z, Cao J. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv. 23(9), 3665–3673 (2016).
  Medline CASGoogle Scholar
• 93. Cheng Y, Zhao P, Wu S et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int. J. Pharm. 545(1–2), 261–273 (2018).
  Medline CASGoogle Scholar
• 94. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 29(6), 1895–1899 (2009).
  Medline CASGoogle Scholar
• 95. Mahmud M, Piwoni A, Filiczak N, Janicka M, Gubernator J. Long-circulating curcumin-loaded liposome formulations with high incorporation efficiency, stability and anticancer activity towards pancreatic adenocarcinoma cell lines in vitro. PLOS ONE 11(12), e0167787 (2016).
  MedlineGoogle Scholar
• 96. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104(6), 1322–1331 (2005).
  Medline CASGoogle Scholar
• 97. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J. Drug Target. 24(3), 179–191 (2016).
  Medline CASGoogle Scholar
• 98. Khalid M, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int. J. Pharm. 528(1–2), 675–691 (2017).
  MedlineGoogle Scholar
• 99. Wu W, Chen M, Luo T et al. ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer. Acta Biomater. 103, 259–271 (2020).
  Medline CASGoogle Scholar
• 100. Tsai Y-M, Chien C-F, Lin L-C, Tsai T-H. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration. Int. J. Pharm. 416(1), 331–338 (2011).
  Medline CASGoogle Scholar
• 101. Chen X-P, Li Y, Zhang Y, Li G-W. Formulation, characterization and evaluation of curcumin-loaded PLGA-TPGS nanoparticles for liver cancer treatment. Drug Des. Devel. Ther. 13, 3569–3578 (2019).
  Medline CASGoogle Scholar
• 102. Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J. Mater. Chem. B 3(39), 7724–7733 (2015).
  Medline CASGoogle Scholar
• 103. Xiao B, Han MK, Viennois E et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale 7(42), 17745–17755 (2015).
  Medline CASGoogle Scholar
• 104. Bisht S, Mizuma M, Feldmann G et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther. 9(8), 2255–2264 (2010).
  Medline CASGoogle Scholar
• 105. Ahmad MZ, Alkahtani SA, Akhter S et al. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J. Drug Target. 24(4), 273–293 (2016). •• Review the recent development in the field of nanoCUR (NanoCur), including polymeric micelles, liposome, polymeric NPs, nanoemulsion, nanosuspension, solid lipid NPs (SLNPs), polymer conjugates, nanogel, etc. in anticancer application.
  Medline CASGoogle Scholar
• 106. Rabiee N, Deljoo S, Rabiee M. Curcumin-hybrid nanoparticles in drug delivery system. Asian J. Nanosci. Mater. 2, 66–91 (2018). •• Reviews a number of formulated hybrid nanoparticles and their efficacy in specific targeting to cancerous cells.
  Google Scholar
• 107. Zhang HY, Sun CY, Adu-Frimpong M, Yu JN, Xu XM. Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: preparation, characterization, cellular uptake and bioavailability evaluation. Int. J. Pharm. 555, 270–279 (2019).
  Medline CASGoogle Scholar
• 108. Zhang J, Li J, Shi Z et al. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater. 58, 349–364 (2017).
  Medline CASGoogle Scholar
• 109. Yang X, Li Z, Wang N et al. Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Sci. Rep. 5(1), 10322 (2015).
  Medline CASGoogle Scholar
• 110. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf. B Biointerfaces 132, 138–145 (2015).
  Medline CASGoogle Scholar
• 111. Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: A multifunctional mediator of cancer progression. Biomolecules 11(12), 1850 (2021).
  MedlineGoogle Scholar
• 112. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44⁺ stem-like pancreatic cancer cells. Biomacromolecules 16(9), 3042–3053 (2015).
  Medline CASGoogle Scholar
• 113. Gao Y, Zhu Y, Xu X et al. Surface PEGylated cancer cell membrane-coated nanoparticles for codelivery of curcumin and doxorubicin for the treatment of multidrug resistant esophageal carcinoma. Front. Cell Dev. Biol. 9, 688070 (2021).
  MedlineGoogle Scholar
• 114. Niu B, Li M, Jia J, Zhang C, Fan Y-Y, Li W. Hydrophobin-enhanced stability, dispersions and release of curcumin nanoparticles in water. J. Biomater. Sci. Polym. Ed. 31(14), 1793–1805 (2020).
  Medline CASGoogle Scholar
• 115. Chen Y, Lu Y, Lee RJ, Xiang G. Nano encapsulated curcumin: and its potential for biomedical applications. Int. J. Nanomed. 15, 3099–3120 (2020). •• Review on the recent development of nanoencapsulated curcumin and its potential for biomedical applications.
  Medline CASGoogle Scholar
• 116. Wei X, Senanayake TH, Bohling A, Vinogradov SV. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition. Mol. Pharm. 11(9), 3112–3122 (2014).
  Medline CASGoogle Scholar
• 117. Rao KM, Rao KK, Ramanjaneyulu G, Ha C-S. Curcumin encapsulated pH sensitive gelatin based interpenetrating polymeric network nanogels for anti cancer drug delivery. Int. J. Pharm. 478(2), 788–795 (2015).
  MedlineGoogle Scholar
• 118. Rejinold NS, Thomas RG, Muthiah M et al. Anti-cancer, pharmacokinetics and tumor localization studies of pH-, RF- and thermo-responsive nanoparticles. Int. J. Biol. Macromol. 74, 249–262 (2015).
  MedlineGoogle Scholar
• 119. Yallapu MM, Ebeling MC, Khan S et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol. Cancer Ther. 12(8), 1471–1480 (2013).
  Medline CASGoogle Scholar
• 120. Guerrero S, Inostroza-Riquelme M, Contreras-Orellana P et al. Curcumin-loaded nanoemulsion: a new safe and effective formulation to prevent tumor reincidence and metastasis. Nanoscale 10(47), 22612–22622 (2018).
  Medline CASGoogle Scholar
• 121. Suwannateep N, Banlunara W, Wanichwecharungruang SP, Chiablaem K, Lirdprapamongkol K, Svasti J. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J. Control. Rel. 151(2), 176–182 (2011).
  Medline CASGoogle Scholar
• 122. Sesarman A, Tefas L, Sylvester B et al. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells. Pharmacol. Rep. 70(2), 331–339 (2018).
  Medline CASGoogle Scholar
• 123. Tian MP, Song RX, Wang T, Sun MJ, Liu Y, Chen XG. Inducing sustained release and improving oral bioavailability of curcumin via chitosan derivatives-coated liposomes. Int. J. Biol. Macromol. 120(Pt A), 702–710 (2018).
  Medline CASGoogle Scholar
• 124. Alizadeh AM, Khaniki M, Azizian S, Mohaghgheghi MA, Sadeghizadeh M, Najafi F. Chemoprevention of azoxymethane-initiated colon cancer in rat by using a novel polymeric nanocarrier–curcumin. Eur. J. Pharmacol. 689(1–3), 226–232 (2012).
  Medline CASGoogle Scholar
• 125. Tomeh MA, Hadianamrei R, Sun W, Xu D, Brown S, Zhao X. Stiffness-tuneable nanocarriers for controlled delivery of ASC-J9 into colorectal cancer cells. J. Colloid Interface Sci. 594, 513–521 (2021).
  Medline CASGoogle Scholar
• 126. Le TT, Kim D. Folate-PEG/Hyd-curcumin/C18-g-PSI micelles for site specific delivery of curcumin to colon cancer cells via Wnt/beta-catenin signaling pathway. Mater. Sci. Eng. C Mater. Biol. Appl. 101, 464–471 (2019).
  Medline CASGoogle Scholar
• 127. Sadeghi-Abandansari H, Pakian S, Nabid M-R, Ebrahimi M, Rezalotfi A. Local co-delivery of 5-fluorouracil and curcumin using Schiff’s base cross-linked injectable hydrogels for colorectal cancer combination therapy. Eur. Polym. J. 157, 110646 (2021).
  CASGoogle Scholar
• 128. Borah PK, Das AS, Mukhopadhyay R, Sarkar A, Duary RK. Macromolecular design of folic acid functionalized amylopectin–albumin core–shell nanogels for improved physiological stability and colon cancer cell targeted delivery of curcumin. J. Colloid Interface Sci. 580, 561–572 (2020).
  Medline CASGoogle Scholar
• 129. Seok HY, Sanoj Rejinold N, Lekshmi KM, Cherukula K, Park IK, Kim YC. CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: in vitro and in vivo evaluation. J. Control. Rel. 280, 20–30 (2018).
  Medline CASGoogle Scholar
• 130. Madhusudana Rao K, Krishna Rao KS, Ramanjaneyulu G, Ha CS. Curcumin encapsulated pH sensitive gelatin based interpenetrating polymeric network nanogels for anti cancer drug delivery. Int. J. Pharm. 478(2), 788–795 (2015).
  MedlineGoogle Scholar
• 131. Akhtar S, Asiri S, Khan FA et al. Formulation of gold nanoparticles with hibiscus and curcumin extracts induced anti-cancer activity. Arabian J. Chem. 15(2), 103594 (2022).
  CASGoogle Scholar
• 132. Beyene AM, Moniruzzaman M, Karthikeyan A, Min T. Curcumin nanoformulations with metal oxide nanomaterials for biomedical applications. Nanomaterials 11(2), 460 (2021).
  Medline CASGoogle Scholar
• 133. Elfadadny A, El-Husseiny HM, Abugomaa A et al. Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives. Environ. Sci. Pollut. Res. Int. 28, 49447–49466 (2021).
  Medline CASGoogle Scholar